Thiazolidinediones for the treatment of type 2 diabetes

European Journal of Internal Medicine

Volumn 18, Issue 1, 2007, Pages 18-25

  Elte, J W F ^a   Blickle J F ^b  

^a SINT FRANCISCUS GASTHUIS   (Netherlands)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Cardiovascular risk; Metabolic syndrome; Thiazolidinediones; Type 2 diabetes

Indexed keywords

ADIPOCYTOKINE; GLIBENCLAMIDE; GLICLAZIDE; GLITAZONE DERIVATIVE; METFORMIN; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SULFONYLUREA;

APOPTOSIS; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR RISK; CELL FUNCTION; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG METABOLISM; FLUID RETENTION; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 33846069095     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2006.09.007     Document Type: Review

References (62)

1. Reaven G.M. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
2. UK prospective diabetes study (UKPDS) group. Overview of 6 years therapy of type 2 diabetes: a progressive disease. Diabetes 44 (1995) 1249-1250
3. UK prospective diabetes study (UKPDS) group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
4. UK prospective diabetes study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
5. Buchanan T.A., Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51 (2002) 2796-2803
6. Ovalle F., and Bell D.S.H. Clinical evidence of thiazolidinedione-induced improvement of pancreatic β-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 4 (2002) 56-59
7. Suwattee P., DeSouza C., Asnani S., Gilling L., and Fonseca V.A. Cardiovascular effects of thiazolidinediones. Endocrinologist 12 (2002) 126-134
8. Dormandy J.A., Charbonnel B., Eckland D.J.A., Erdmann E., Massi-Benetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366 (2005) 1279-1289
9. Barman-Balfour J.A., and Plosker G.L. Rosiglitazone. Drugs 57 (1999) 921-930
10. Gillies P.S., and Dunn C.J. Pioglitazone. Drugs 60 (2000) 333-343
11. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferators-activated receptor γ (PPARγ). J Biol Chem 270 (1995) 12953-12956
12. Vamecq J., and Latruffe N. Peroxisome proliferators-activated receptors (PPARs) and their implications in diseases. Curr Opin Endocrinol Diabetes 7 (2000) 8-18
13. Tan M.H. How pioglitazone affects glucose and lipid metabolism. Exp Clin Endocrinol Diabetes 108 suppl 2 (2000) S224-S233
14. Tan M.H., Baksi A., Krahulec B., Kubalski P., Stankiewicz A., Urquhart R., et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 28 (2005) 544-550
15. Hanefeld M., et al., on behalf of the QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27 (2004) 141-147
16. Khan M.A., St. Peter J.V., and Xue J.L. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25 (2002) 708-711
17. van Wijk J.P.H., de Koning E.J.P., Castro Cabezas M., and Rabelink T.J. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 28 (2005) 844-849
18. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
19. Raji A., Seely E.W., Bekins S.A., Williams G.H., and Simonson D.C. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 26 (2003) 172-178
20. Bennett S.M.A., Agrawal A., and Elashat H. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med 21 (2004) 415-422
21. Sarafidis P.A., Lasaridis A.N., Nilsson P.M., Pagkalos E.M., Hitoglou-Makedou A.D., Pliakos C.I., et al. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 22 (2004) 1769-1777
22. St John Sutton M.J., Rendell M., Dandona P., Dole J.F., Murphy K., Patwardhan R., et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 25 (2002) 2058-2064
23. Bakris G., Viberti G., Weston W.M., Heise M., Porter L.E., and Freed M.I. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 17 (2003) 7-12
24. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., and Freed M.I. for the rosiglitazone clinical trials study group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 280-288
25. Freed M., Fuell D., Menci L., Heise M., and Goldstein B. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes (Abstract). Diabetologia 43 Suppl. 1 (2000) A267 poster 1024
26. Miyazaki Y., Mahankali A., Wajcberg E., Bajaj M., Mandarino L.J., and DeFronzo R.A. Effects of pioglitazone on circulating adipocytokine levels and insulin sensitivity in Type 2 diabetic patients. J Clin Endocrinol Metab 89 (2004) 4312-4319
27. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Fred M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
28. Miyazaki Y., Mahankali A., Matsuda M., Mahankali S., Hardies J., Cusi K., et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87 (2002) 2784-2791
29. Bays H., Mandarino L., and DeFronzo R. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89 (2004) 463-478
30. Minamikawa J., Tanaka S., Yamauchi M., Inoue D., and Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83 (1998) 1818-1820
31. Koshiyama H., Shimono D., Kuwamura N., Minamikawa J., and Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 3452-3456
32. Sidhu J.S., Kaposzta Z., Markus H.S., and Kaski J.C. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24 (2004) 930-934
33. Nakamura T., Matsuda T., Kawagoe Y., Ogawa H., Takahashi Y., Sekizuka K., et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 53 (2004) 1382-1386
34. Langenfeld M.R., Forst T., Hohnberg C., Kann P., Lübben G., Konrad T., et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Results from a controlled randomized study. Circulation 111 (2005) 2525-2531
35. Pfützner A., Marx N., Lübben G., Langenfeld M., Walcher D., Konrad T., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemiuc control. J Am Coll Cardiol 45 (2005) 1925-1931
36. Choi D., Kim S.-.K., Choi S.-H., Ko Y.G., Ahn C.W., Jang Y., et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27 (2004) 2654-2660
37. Osman A., Otero J., Brizolara A., Waxman S., Stouffer G., Fitzgerald P., et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 147 (2004) 21-25
38. Marx N., Wöhrle J.H., Nusser T., Walcher D., Rinker A., Hombach V., et al. Pioglitazone reduces neointima volume after coronary stent implantation. A randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112 (2005) 2792-2798
39. Wang G.M., Wei J., Guan Y., Jin N., Mao J., and Wang X. Peroxisome proliferator-activated receptor-y agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metab Clin Exp 54 (2005) 590-597
40. Smith S.A., Lister C.A., Toseland C.D.N., and Buckingham R.E. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2 (2000) 363-372
41. Ozawa S., Takizawa M., Itoh E., Katsuta H., Tanaka T., Yamaguchi S., et al. The protective effect of the long-term treatment by pioglitazone on the insulin secretory capacity and β cell mass in obese diabetic db/db mice. Diabetes 51 suppl 2 (2002) A 361 poster 1476-P
42. Porter L.E., Freed M.I., and Jones N.P. Rosiglitazone reduces proinsulin/insulin ratio and improves β-cell function in type 2 diabetes. Diabetologia 43 suppl 1 (2000) A192 poster 737
43. Rosenstock J., and for the pioglitazone HCI study group. Improved insulin sensitivity and beta cell responsivity suggested by homa analysis of pioglitazone therapy. Diabetologia 43 suppl 1 (2000) A192 poster 738
44. Matthews D.R. Insulin resistance and β-cell function - a clinical perspective. Diabetes Obes Metab 3 suppl. 1 (2001) S28-S33
45. Miyazaki Y., Matsuda M., and DeFronzo R.A. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25 (2002) 517-523
46. Juhl C.B., Hollingdal M., Pørksen N., Prange A., Lönnqvist F., and Schmitz O. Influence of rosiglitazone treatment on β-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 88 8 (2003) 3794-3800
47. Leiter L.A. β-cell preservation: a potential role for thiazolidinediones to improve clinical care in type 2 diabetes. Diabet Med 22 (2005) 963-972
48. Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet 366 (2005) 1241-1242
49. Fonseca V., Jawa A., and Asnani S. Commentary: the PROactive study - the glass is half full. J Clin Endocrinol Metab 91 (2006) 25-27
50. Ceriello A. PROactive study : (r)evolution in the therapy of diabetes ?. Diabet Med 22 (2005) 1463-1464
51. Scheen A.J. Hepatotoxicity with thiazolidinediones. Is it a class effect?. Drug Safety 24 (2001) 873-888
52. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., et al. Thiazolidinedione use, fluid retention, and congestive heart failure. Circulation 108 (2003) 2941-2948
53. Nakamura T., Funahashi T., Yamashita S., Nishida M., Nishida Y., Takahashi M., et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation-double-blind placebo-controlled trial. Diabetes Res Clin Pract 54 (2001) 181-190
54. IDF. A desktop guide to type 2 diabetes. Diabet Med 16 (1999) 716-730
55. Rosenstock J., Sugimoto D., Strange P., Stewart J., Soltes-Rak E., and Dailey G. Triple therapy in type 2 diabetes (T2DM): benefits of insulin glargine (GLAR) over rosiglitazone (RSG) added to combination therapy of sulfonylurea plus metformin (SU + MET) in insulin-naïve patients. Diabetes suppl. 3 (2004) poster 609
56. Neeser K., Lübben G., Siebert U., and Schramm W. Cost effectiveness of combination therapy with Pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. PharmacoEconomics 22 (2004) 321-341
57. Henriksson F. Applications of economic models in healthcare. The introduction of Pioglitazone in Sweden. PharmacoEconomics 20 Suppl 1 (2002) 43-53
58. Coyle D., Palmer A.J., and Tam R. Economic evaluation of Pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. PharmacoEconomics 20 Suppl 1 (2002) 31-42
59. Kalkesar I., Iyer S., Mody R., Rajagopalan R., and Kavookjian J. Utilization and costs for compliant patients initiating therapy with Pioglitazone or Rosiglitazone versus insulin in a Medicaid fee-for-service population. J Manag Care Pharm 12 (2006) 121-129
60. Bottomley J., Palmer A.J., Williams R., Dormandy J., and Massi-Benedetti M. PROactive 03: pioglitazone, type 2 diabetes and reducing macrovascular events - economic implications?. Br J Diabetes Vasc Dis 6 (2006) 63-70
61. Kendall D.M. Thiazolidinediones. The case for early use. Diabetes Care 29 (2006) 154-157
62. Ovalle F., and Ovalle-Berúmen J.F. Thiazolidinediones: a review of their benefits and risks. South Med J 95 (2002) 1188-1194